life scienc tool diagnost
quest mid-west ndr takeaway
investor meet highlight host investor meet vice-president ir
shawn bevec mid-west walk away increment posit
growth prospect lap headwind driver ramp
volum in-network access consumer-centr initi dedic cost
save initi capit deploy option reimburs
pressur recent payer contract shift spur consolid
somewhat transit year driver support
top-lin growth organ earn growth longer term
dynam in-network access insur live
last year associ volum influx progress accord
plan initi healthi kickoff new payer contract januari
sequenti improv februari march dynam ramp
throughout year increment pln volum also build
measur pace intent pln incentiv physician
patient use lower cost prefer partner await detail
specif incent leverag steer volum note make
chang annual ep adjust quarterli expect
align progress calendar day
build volum in-network access/pln lap certain
headwind said rais tp
ebitda enhanc clariti nt growth prospect
capit deploy kicker valuat pama headwind
well-docu remain variabl term
impact continu forecast increment cut earli
junctur could prove conserv broadli optimist
step activ post-pama world offset
longer term reimburs pressur less effici lab oper
exacerb payer shift dgx share ytd vs
current trade ebitda five-year average
essenti pariti labcorp contribut neutral
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
provid diagnost test informatin
price may rate neutral target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform could come faster
organ growth gain in-network statu
sentiment could drive upsid target price blue sky
scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
host investor meet dgx ir maven shawn bevec across mid-west
dgx longer term driver broadli intact greater in-network access continu
innov consumer-centr initi capit deploy particularli relev
quarterli dynam
april report ep ahead consensu
estim higher revenu off-set lighter compar profit
factor line drive beat
revenu growth bright spot nice forecast
experienc bp tailwind favor weather off-set one less sell
day quarter bp headwind impli bp normal organ growth
experi well origin organ growth forecast manag
larg attribut organ growth strength increas access explicitli quantifi
increment in-network member new contract also note stabl demand
trend across broader industri
also highlight revenue/access declin better plan repres
improv experi year-over-year declin attribut
increment reimburs pressur relat pama well higher patient
gross margin drop bp albeit higher anticip
bp administr expens rose bp compar basi
wors forecast bp despit on-going cost cut neg impact
million associ defer comp off-set line compar ebitda
margin deterior bp bp plan overal profit impact
increment price headwind bp oper margin meanwhil patient
concess neg impact revenu bp essenti drop bottom
line note guidanc assum bp impact year patient
concess like neutral impact lap prior year sizeabl headwind
broadli collect rate patient broadli chang
dollar size increas owe part prolifer util
note earn back-end weight particularli lap notabl headwind
patient concess denial incur new in-network volum ramp
term relev calendar shift also extra calendar day benefit
juli face unfavor comparison due time
experienc initi healthi kickoff jump new payer contract
januari explicitli quantifi help earli educ effort
sequenti improv februari march continu build throughout
year line previou manag commentari
in-network access expand meaning year includ roughli
insur live us last year follow newli sign agreement
bcb new jersey bcb georgia repres increment
million in-network member largest year-over-year increas access in-network
live decad
consist prior compani commentari estim three new contract
repres billion revenu opportun aim captur
potenti opportun in-lin current market share within independ lab
segment captur roughli share aforement billion
opportun impli could achiev increment million revenu end
repres growth
increment steer volum new pln common investor question
throughout meet clearli intent pln better incentiv physician
patient use effici lower cost pln partner point
formal disclos exactli accomplish await greater detail
opportun net/net increment pln-associ volum build
time note broadli physician gener awar pln yet
ahead juli implement potenti greater physician patient awar
around dispar across industri price detail recent lay press articl
want secret common blood test
almost could also help steer volum low cost provid
current discuss similar pln concepts/value-bas contract two
major payer view unh pln could drive broader market trend payer seek
way better control clinic laboratori spend healthcar expenditur area
rel unmanag broadli ineffici market compet hospit
outreach lab cost nation clinic laboratori
price alreadi lock chang particip
pln incorpor meaning volum lift pln await
detail network implement
remind april unitedhealthcar unveil relev clinic laboratori
constitu particip pln effect juli broadli anticip
lh includ ameripath/dermpath subsidiari includ along
bioreference/genedx mayoclin laboratori latter two like
play narrow role pln given specialty/region focu
pama broadli embed investor expect continu forecast
cut medicar price could opportun
pama relief incorpor expect junctur
remind april american clinic laboratori associ acla present
oral argument us court appeal aim overturn prior judg
decis throw case due jurisdict issu remind septemb
us district court district columbia dismiss lawsuit brought forth
acla reform propos rate cut part clinic lab fee schedul
clf pama court held acla testimoni rais pertin
question ultim conclud author act matter
pama inher less visibl potenti impact pama
beyond maximum cut move
recalcul rate could actual result less oner cut regardless clearli
magnitud dollar impact less contribut medicar shrink
maintain view cut could ultim prove
conserv depend mix/outcom recalcul
relationship locat note work
potenti expand healthcar offer in-stor current blood-draw center better
leverag phlebotomist could assist basic vital screen blood pressur
weight broader well exam safeway ration
safeway servic locat outperform
remind test site co-loc select
safeway locat across us note current maintain roughli
psc retail set aim expand retail co-
locat psc view ration overal psc footprint
also achiev better overal custom access note remain open partner
retail pharmaci besid safeway view
partnership could develop time albeit noth new discuss
front meet
remain nomin current offer
questdirect state consum may choos test packag includ
gener health men women health digest health heart health infecti
diseas sexual transmit diseas test current valu consum
initi test opportun million today grow dd albeit small base
invigor cost save initi track aim take cost
cost base annual basi launch cost effici program invigor
aim drive cost save also improv performance/product
broadli key initi focu organiz optim inform technolog
procur field custom servic lab excel revenu servic note
exit total estim run-rat save excess billion sinc
hit inflect point industri consolid near term common
question laboratori consolid clearli new thesi continu
view verg meaning consolid fuel pama
contract shift weigh lab competitor far inferior cost structur
 remain key compon dgx growth strategi add least
bp top-lin growth annual importantli achiev
acquisit relat revenu growth nine independ deal alreadi
achiev expect growth acquisit embed guidanc
continu view pama newli non-exclus manag care contract spur
greater market consolid height reimburs cut greater
in-network access labcorp disproportion pressur smaller lab
pressur prescript drug monitor may eas near term lap
headwind associ chang reimburs presumpt screen last
year payer revers prior chang
vitamin start lap headwind associ chang vitamin
test coverag howev aetna last major payor move
restrict coverag polici occur dynam embed
compani guidanc
monet data contribut effort leverag data asset remain low
earli day incorpor data offer payer contract sell
note dia cro industri confer june last year launch quest
clinic trial connect offer diagnost data partner
continu view need necessarili cro leverag
data asset rather take agnost approach emphas potenti
compel opportun partner sever
figur ev/ebitda ratio lh
compani mention price
labcorp america lh
